The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
£23mil market cap is just far, far too low for 75mmboe - with a partner of Shell, one of the Super majors.
Will be much higher by the close on Monday - there is no doubt in my mind
vox markets podcast sarup
3D Seismic over the summer, then takes quite a while to properly analyse 3D seismic data - it will be a vast amount.
That will take us to Q3-Q4 2019. It's then 1 year window to drill the well (which can take a while, look at Serica drill - 140 days for Rowallan spud - which may add 20mmboe. Big drills take time).
Perfectly normal.
What news channel was it on please?
Results on the 6th of Feb
Finally some movement today. Quite frankly I am amazed this isn't trading higher.
On a 2020 PE of 5 according to Finncap!!
We're 85% gas production atm Monty so POO thankfully not too important currently.
Highest ever price now paid. Expect more acquisitions in due course.
very quiet today
Chevron's stake in Erskine is up for sale. Think we might try and get it?
Chevron is notably the operator so we'd have to take up that mantle.
I suppose we might be focusing on bigger assets than Erskine at this stage? Mitch said we've just begun our acquisition programme - ready to move onto the next level.
Has swung up 5% already from lows. This looks like just a shake cf456. Should be a strong afternoon I hope. Potentially an easy swing trade if you were able to grab when it was down 10%
and there we go, that institutional buying...
Agree, looks like a few traders off for the next punt coupled with a bit of institutional selling, presumably from the placing in august.
Reasonable to expect more institutional buying time which is what tends to really shift this.
Full Article:
Avacta
The catalog of anti-idiotypic reagents has been expanded to include the therapeutic targets adalimumab, ipilimumab, and rituximab. These anti-ID Affimer® reagents have been developed in collaboration with leading CROs and pharmaceutical companies. They offer a number of benefits, including: highly specific and sensitive recognition of your therapeutic antibody with a generic detection system to overcome the need for bridging assays and simplify assay set-up, low matrix effect to ensure assay performance within a range of complex samples, and batch-to-batch consistency assuring the security of supply. The company is expanding its range of anti-ID reagents to include more therapeutic antibody targets and Affimer reagent binding modes. Lastly a custom anti-ID development service offers rapid development of reagents, with no affinity maturation needed.
Co looking to hire a fair amount of staff. Firmly in growth mode..
https://www.avacta.com/careers?utm_content=79465401&utm_medium=social&utm_source=twitter
And another! 60k buy this time. Someone loading up.
More and more late reported huge trades coming through all the time. 50k buy since I wrote that last post!
Clearly more institutional buying today as well with those big round trades in the the £10s of thousands
Great breakout yesterday. Completing the backtest today which is good to see. Nice safe entry or top up price from a technical analysis point of view.